Targeting several cell surface RTKs simultaneously, in addition to EGFR, or inactivating intracellular kinases that function as converging hubs of deregulated signalling pathways may be an effective therapeutic strategy for treating FLCN-dependent renal cell cancers. Here, FLCN is linked to renal cell adenocarcinoma.